Weekly Market Snapshot 23 July 2010 James Hutson Stress Test The FTSE 100 staged a small recovery through the last week up +1.97% to Thursday’s Adam Sketchley close. The positive move higher was driven by the miners, with Antofagasta up +11.6% and Kazakhmys up +10.7%. Government Bonds also produced some positive momentum over Alex Holbech the week, with yields broadly declining across the board. Meanwhile, Gold continued its bearish retracement, with the price of Brent Crude progressing higher. On Friday, despite Charlotte Watson UK Q2 GDP coming in at 1.1%, nearly twice market expectations, the UK equity market continued to trade broadly flat at midday as investors braced themselves for the publication
Tel: 0117 933 0020 of the European bank stress tests results (due out later today). Some 91 European banks have been tested, and some are expected to fail those capital tests. Recapitalisations of any failing banks could mean a call on markets, but also on the €750bn EU/IMF fund set up a Source: DataStream couple of months ago. Back here in the UK, the recent and severe refinancing of our own tattered banking sector means little chance of failures here. For our mind, the most sensible UK bank to play remains HSBC given its broad product array, global reach, solid capital and liquidity position, and emerging market/Asian exposure. The week ahead Key economics - The week gets off to a quiet start, with US Homes sales data on Monday where
consensus expectations are looking for a positive rise of +20K from the previous figure of 300K.
On Tuesday we expect US Consumer Confidence numbers, where consensus expectations are
08-Jul 10-Jul 12-Jul 14-Jul 16-Jul 18-Jul 20-Jul 22-Jul
forecasting a moderate decline to 52.0 from 52.9. Economic releases gather momentum onWednesday with German CPI and US Durable Goods figures. On Thursday, we expect the
Market Performance (%) Source: DataStream
release of the GFK Consumer Confidence data before Friday's US GDP and Michigan Sentiment
S&P 500 National Grid (NG.L) - The utility company is expected to release an IMS on Tuesday. After the NIKKEI 225
recent £3.2bn rights issue the company is planning to buy back some €450mn of its short dated
MSCI EUROPE
bonds due to its long cash position which should help reduce the redemption burden over the
coming years. On valuation, the stock currently trades on a PE of 10.4x and a PEG of 1.5x one
year out, with a dividend yield of 7.1%. Bond Yields BP (BP.L) - The embattled energy giant is expected to announce Q2 results on Tuesday. The Source: DataStream
Group recently announced the sale of $7 billion of assets to the Apache Corporation in order to
Benchmark UK
provide further funds to meet liabilities caused by the Gulf of Mexico oil spill. Caution surrounds the
tropical storm Bonnie and the knock on impact of the temporary suspension of operations in the
Gulf region. On valuation, the stock currently trades on a PE of 6.7x and a PEG of 0.4x one year
Benchmark US Benchmark EU Benchmark JP Centrica (CNA.L) - The integrated energy company is expected to releases results on Wednesday IBoxx Corp UK
and forms a core holding within the RD Balanced Model Portfolio. Positive news recently emergedregarding the Upstream business, with an encouraging second appraisal of a Gas well in the North
Currency (% change)
Sea. On valuation, the stock currently trades on a PE of 12.8x and a PEG of 1.3x one year out,
Source: DataStream AstraZeneca (AZN.L) - The recently announced Crestor patent litigation victory produced a
positive reaction by investors, helping to drive the share price higher. Broker comments have also
been rather positive, focusing on the likely success of ongoing litigation and FDA approval cases. The pharmaceutical giant has been a recent addition into the RD Balanced Model Portfolio. On
Commodities (absolute change) Source: DataStream
valuation, the stock currently trades on a PE of 8x 2011E with a dividend yield of 4.9%. Brent, curr ($)
Added to conviction list: National Grid 01/06/2010 444p, BP 09/06/2009 530p, Centrica 09/06/2009 231p, AstraZeneca21/06/2010 3044p
Soya bean (c) VIX (equity volatility) Source: DataStream UK Top Risers & Fallers Source: DataStream Sub sectors: top 3 risers (1w) Sub sectors: top 3 fallers (1w) Corporate Calendar Source: Thomson 26/07/2010 27/07/2010 Ex Dividend 28/07/2010 29/07/2010 30/07/2010 Economics Calendar Date Estimated 26/07/2010 27/07/2010 28/07/2010 29/07/2010
GBP - M4 Money Supply (Final) (Jun) (MoM)
GBP - M4 Money Supply (Final) (Jun) (YoY)
30/07/2010
USD - University of Michigan Sentiment (F) (Jul)
Source: DataStream Market Performance (% change) Source: DataStream FTSE ALL SHARE FTSE SMALL CAP FTSE AIM ALL-SHARE UK Sector Performance Absolute performance (£ %) Relative performance (£ %) Oil & Gas
Oil Equipment, Services & Distribution
Basic Materials Industrials Consumer Goods Health Care Consumer Services Telecommunications Utilities Financials Technology
Key: CAGR = Compound Annual Growth Rate, RY = Redemption Yield, PBT = Pre Tax Profit
This publication is provided solely to assist clients to make their own investment decisions. It may therefore not be suitable for all recipients and does not constitute a personal recommendation to invest. If you have any doubts as to the suitability of these investments, you should seek advice from your adviser. The past is not necessarily a guide to future performance. The value of shares and the income from them can fall as well as rise and investors may get back less than they originally invested. Any tax reliefs referred to are those currently applying. All estimates and prospective figures quoted in this publication are forecast and are not guaranteed. Rowan Dartington, its associate companies and/or their clients, directors and employees may own or have a position in the securities mentioned herein and may add to or dispose of any such securities. Rowan Dartington is the trading name of Rowan Dartington & Co Limited. Registered in England & Wales No. 2752304 at Colston Tower, Colston Street, Bristol, BS1 4RD. Rowan Dartington Limited is authorised and regulated by the Financial Services Authority.
The aim of drug therapy is in general to cure diseases or reduce symptoms. However, drug therapy is ineffective in 30 to 60 percent of the patients and, on the other hand, two to four percent of all hospital admissions result from adverse drug reactions. A better prediction which patients will not respond to drug therapy or will develop adverse drug reactions may avoid these events ( chapter 1
Tratamento da Doença de Parkinson Henrique Ballalai Ferraz* A doença de Parkinson (DP) é uma moléstia de curso progressivo, geral-A levodopa ainda é a pedra angular do trata-mente com início assimétrico em uma metade do corpo. Pode manifestar-semento da doença de Parkinson apesar de seuuso por longo prazo não ser isento de pro-combinando dois ou mais dos seguintes sinais: tremor de